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Asthma and hypertension are complex diseases coinciding more frequently than expected by chance. 
Unraveling the mechanisms of comorbidity of asthma and hypertension is necessary for choosing the 
most appropriate treatment plan for patients with this comorbidity. Since both diseases have a strong 
genetic component in this article we aimed to find and study genes simultaneously associated with 
asthma and hypertension. We identified 330 shared genes and found that they form six modules on 
the interaction network. A strong overlap between genes associated with asthma and hypertension 
was found on the level of eQtL regulated genes and between targets of drugs relevant for asthma 
and hypertension. this suggests that the phenomenon of comorbidity of asthma and hypertension 
may be explained by altered genetic regulation or result from drug side effects. In this work we also 
demonstrate that not only drug indications but also contraindications provide an important source of 
molecular evidence helpful to uncover disease mechanisms. These findings give a clue to the possible 
mechanisms of comorbidity and highlight the direction for future research.
Asthma and hypertension affect hundreds of millions of people worldwide1,2 and coincide in adults more fre-
quently than expected by chance. Patients with asthma are more likely to have high blood pressure3 and, in 
turn, the presence of hypertension is associated with the increased severity of asthma4. This association between 
asthma and hypertension was confirmed in multiple studies of different patient cohorts3–7 but its underlying 
causes remain unknown. The coexistence of two or more diseases, called comorbidity, was shown for many 
human disorders8–10. Moreover, not only complex disorders demonstrate comorbidity but also several Mendelian 
diseases coincide with complex disorders10,11. Comorbidity can be direct or inverse8,12, when the presence of one 
disease protects from the development of another one. For example, the coincidence of neoplasms with several 
nervous system disorders is lower than expected13,14.
Comorbidity may point to causal relationships between two diseases. For instance, hypertension may cause 
cardiovascular damage, leading to consequences such as heart failure, stroke, and kidney problems2. Alternatively, 
comorbidity may result from confounder effects, e.g. lifestyle or environmental factors, predisposing to multi-
ple health problems. For instance, smoking is a risk factor for multiple diseases15, including hypertension2 and 
asthma1. Also, stress may trigger asthma attack1, and long-term stress exposure is associated with the risk of 
hypertension2. Finally, comorbidity of two diseases may be an effect of a third disease. For instance, obesity is 
another common risk factor for asthma and hypertension and decreasing of the body-mass index is helpful for 
management of both diseases16,17.
In addition to these risk factors, some anti-asthmatic drugs may worsen hypertension and vice versa, and 
several anti-hypertensive drugs are contraindicated in asthma. For example, beta-blockers used to control blood 
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pressure can cause asthma attacks18,19 and therefore are contraindicated for asthma patients. At the same time, 
beta-agonists, used for treatment of asthma may increase heart rate20 and should be used with caution in patients 
with hypertension. Corticosteroids are aimed at suppressing the immune system and are used against asthma1, but 
can at the same time elevate blood pressure due to their effect on kidneys, leading to enhanced liquid retention21.
Nevertheless, comorbidity between asthma and hypertension can only in part be explained by excessive 
weight, smoking and the use of specific drugs and persists after consideration of these variables, although 
becomes weaker4. Besides environmental risk factors, including other diseases and drugs, comorbidity may arise 
as the result of shared molecular genetic basis22, predisposing the patient to the development of both diseases. 
Comorbid diseases may share associated genes themselves23–25 or demonstrate strong connectivity between two 
sets of associated genes in protein interaction11,26–29, gene coexpression26 or metabolic networks30.
Recent studies have shown that many epidemiologically correlated diseases and traits share risk loci identified 
in genome-wide association studies (GWAS)31,32, but this is not true for hypertension and asthma31. However, 
GWAS results are not the only information source of gene-disease associations. Many different approaches are 
used to establish associations between genes and diseases. For example, genes altering expression in disease and 
genes encoding drug targets are likely to be also involved in its pathogenesis.
Despite the fact that many genes are associated with isolated asthma and hypertension, molecular mechanisms 
underlying their comorbidity remain unclear. To investigate the genetic basis of this comorbidity, we constructed 
comprehensive lists of asthma and hypertension associations of different nature and identified genes implicated 
in both diseases. We analyzed the relationships between these genes, revealed six tightly interconnected gene 
modules and characterized these modules by enriched GO terms, pathways and tissue specificity. Identification of 
the genes and gene modules potentially involved in both disorders may advance the unraveling the mechanisms 
of their comorbidity, and help get further insight into the pathogenesis of asthma and hypertension comorbidity.
Results
Genes previously associated with asthma and hypertension. Although the phenomenon of comor-
bidity of asthma and hypertension has long been known, only a few works discussing genes potentially involved 
in both diseases or related pathophysiological processes have been published before 2018. We have found six 
publications which discussed ten genes in total potentially relevant to both asthma and hypertension and summa-
rized the results of our literature search in Table 1. These studies were mostly focused on genes and their functions 
and did not aim to discover the mechanisms of comorbidity between the two diseases.
In our recent work33, we applied ANDSystem34,35 to perform the automatic reconstruction of the associative 
gene network for asthma and hypertension from scientific literature. The resultant associative network included 
205 genes potentially responsible for comorbid asthma and hypertension. We proposed gene prioritization 
methodology based on ten criteria including relevance scores calculated by state-of-the-art gene prioritization 
tools36,37, association with biological processes, position in the associative network and evidence of genetic asso-
ciations and regulations. The IL10, TLR4, and CAT genes had the highest ranks among all candidate genes, and 
ADRB2 was ranked sixth. Our later works demonstrated experimental evidence supporting possible roles of 
IL10 and TLR4 in comorbid asthma and hypertension. Drevytska et al. created an animal model of comorbid 
asthma and hypertension – SHR with OVA-induced asthma – and demonstrated that IL10 knock-down in this 
model improves cardiac and lung function parameters38. Bragina et al. identified expression quantitative trait 
loci (eQTL) associated with asthma and hypertension comorbidity for CAT, TLR4, ANG and RNASE4 genes on 
the cohort of 587 individuals from West Siberia39. More recently, Saik et al. reanalyzed associative asthma/hyper-
tension network and, based on the cross-talk centrality, proposed ten more immune-related genes for further 
experimental validation40.
All the previous works investigated the genetic basis of asthma/hypertension comorbidity evaluated the rel-
evance of single genes. In contrast with previous studies, in this work, among all the associations extracted from 
a variety of data sources, we identified and characterized groups of functionally related genes. Our approach 
aligns with current understanding of asthma and hypertension as complex disorders, which thought to be poly-
genic and heterogeneous41,42. Yet another advantage of this work is that we incorporated types of associations not 
considered in previous studies nor provided by large gene-disease association portals, such as Open Targets43 or 
DisGeNET44. In particular, we included into the analysis genes controlled by eQTLs associated with asthma and 
hypertension and target genes of drugs contraindicated in these diseases.
the overlap between genes associated with asthma and hypertension independently. Aiming 
to compose comprehensive lists of genes associated with asthma and hypertension and investigate their overlap, 
we collected gene-disease associations supported by a variety of evidence types: genetic associations, differential 
expression, co-occurrence in texts, and targeting by drugs used against asthma and hypertension. Also, to expand 
these gene lists, we used GWAS hits mapped to known eQTLs and selected genes regulated by these eQTLs. 
Finally, we hypothesized, that genes targeted by drugs causing adverse effects similar to asthma and hypertension 
may also be involved in their pathogenesis. Therefore, in addition to drugs that can treat asthma and hyperten-
sion, we took into account drugs that exaggerate these diseases and added their targets in the lists of genes for 
asthma or hypertension.
After combination of gene-disease associations from various evidence sources (see Methods and Fig. 1), 
the lists of 980 genes associated with asthma and 1204 genes associated with hypertension were compiled. Out 
of them, 330 genes were associated with both diseases according to at least one data source (Supplementary 
Table S1). To facilitate further use of associations relevant for asthma and hypertension comorbidity, we added 
them to GenCoNet database45.
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network analysis of shared genes reveals six modules. In order to identify groups of functionally 
related genes, we built a functional network of shared asthma/hypertension genes using Cytoscape46 v3.6.1 strin-
gApp47 v1.3.0 and performed module detection. In this network, two nodes were connected, if corresponding 
genes are co-expressed or if proteins physically interact or share biological pathways. Only edges representing 
gene co-expression, physical interactions of encoded proteins and biological pathway sharing, were included 
in the network. Overall, 257 out of 330 genes (78%) were connected with at least one of other genes. Six tightly 
interconnected modules were detected using ClusterViz App48 v1.0.3 EAGLE algorithm49 (with minimal Clique 
Size and Complex Size thresholds set to 10) and annotated with overrepresented pathways, GO terms, and 
tissue-specific gene sets (Supplementary Tables S2A–C provide all significant gene set overlap analysis results).
Module 1 comprised 77 genes was enriched with genes participating in cytokine signaling, in particular, in IL-
4, IL-13, and IL-23, and Th17 differentiation pathways. IL-4 and IL-13 regulate inflammatory response to allergen 
exposure in asthma50. IL-23 and Th17 cells are elevated in hypertension51 and promote neutrophilic inflammation 
in asthma52. A very recent review on the treatment of comorbid asthma and hypertension summarizes implica-
tions of cytokine signaling and Th17 cells for both diseases53. Module 2 comprised 43 genes participating in the 
metabolism of xenobiotics and defending the cell from oxidative stress. Reactive oxygen species are generated 
by airway epithelium cells exposed to irritants, activate immune cells and thought to be implicated in asthma54. 
Hypertension is characterized by elevated oxidative stress biomarkers in blood and increased oxidative damage of 
vasculature55,56. A large body of evidence confirms roles of antioxidant defence enzymes in asthma57–59 and hyper-
tension60,61. Interestingly, a key antioxidant enzyme, catalase (CAT), was also previously associated with comorbid 
asthma and hypertension33,39. Module 3 enriched with genes involved in extracellular matrix organization and 
platelet degranulation. Platelets are altered in hypertension62 and their release products participate in airway 
inflammation and remodeling in asthma63. Module 4 was enriched by genes encoding G protein-coupled recep-
tors and responsible for regulation of blood vessel diameter. This module included adrenoreceptor genes, many 
of which are targeted by drugs against asthma and hypertension. Module 5 was enriched with genes participating 
Gene Functions Evidence
TLR4 pathogen recognition and activation of innate immunity Up-regulated in lungs of spontaneously hypertensive rats (SHR) 
compared to normotensive ancestor strain (WKY rats) in response 
to combustion source particulate matter treatment which irritates 
lungs96
CXCL2 (MIP-2) suppress hematopoietic progenitor cell proliferation
CD14 mediates the innate immune response to bacterial lipopolysaccharides
RHOA reorganization of the actin cytoskeleton and regulation of cell shape, attachment, and motility
Up-regulated in rodent models of asthma and hypertension; 
inhibition leads to improvement of both conditions97. ROCK 
inhibitors suppress smooth muscle contraction and may treat 
arterial hypertension and asthma98ROCK1 regulates formation of focal adhesions
GNA12, GNA13 signal transduction
These genes encode G-protein subunits transducing the signal from 
activated GPCR to RhoGEFs activating RHOA. Abnormal G12/13 
signaling is involved in the pathogenesis of arterial hypertension 
and bronchial asthma, among other pathophysiological 
conditions99
SLC26A4 encodes transmembrane anion exchanger Madeo et al.
100 reported a variant of SLC26A4 with potentially 
protective effect for both asthma and hypertension
ADRB1, ADRB2 mediate the physiological effects of the epinephrine and norepinephrine
These genes encode proteins targeted by drugs used against asthma 
and hypertension; some variants are associated with response to 
anti-hypertensive101 anti-asthmatic therapy102
Table 1. Genes potentially involved in the pathophysiology of asthma and hypertension, according to literature 
published before 2018.
Figure 1. Identification and characterization of gene modules associated with asthma and hypertension. 
Network nodes represent genes and are colored according to membership in a module. Nodes not assigned to 
clusters are shown in grey. Size of each node is proportional to the number of evidence sources supporting the 
association of corresponding gene with asthma or hypertension. All gene set overlap analysis results are shown 
in Supplementary Tables S2A–C.
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in cytokine signaling. In contrast to module 1, genes from module 5 were associated with interferon gamma 
response and more specific for CD16-monocytes and sputum, than for neutrophils. Interferon-gamma inhib-
its Th2-induced inflammation but promotes cytotoxic response64. Interferon gamma signaling is implicated in 
asthma64 and angiotensin-II-induced hypertension65. Module 6 was composed of genes encoding histones, whose 
modifications define chromatin state and regulate gene expression. Changes of histone modifications are shown 
in many diseases including asthma66 and hypertension67. Inhibition of histone deacetylases decreases inflamma-
tions68 and demonstrate anti-hypertensive effects67,69.
Some modules overlapped in a few genes: MAPK1 and EDN1 belonged to modules 1 and 4, C3 and C5 to 
modules 2 and 4, STAT1 to modules 1 and 5, and SERPINA1 to modules 2 and 3. Such genes may be responsible 
for a cross-talk between biological processes represented by modules these genes connect. However, of these 
six genes, only MAPK1 and STAT1 were associated with asthma or hypertension through evidence other than 
co-occurrence in texts.
Analysis of evidence types supporting gene-disease associations. To investigate the contribution 
of various evidence types to the detection of shared genes, we labeled every gene with the kind of relationship, 
linking it with asthma or hypertension, and analyzed the distribution of labels among six modules. Figure 2 shows 
that the distribution of labels over the network does not seem to be random, and the representations of different 
evidence type labels among modules are not equal. The majority of shared genes (231 of 330) had an association 
established via text mining by HuGE Phenopedia70 v2.1 and were supported by at least two independent studies. 
Moreover, associations of 125 of them were established via text mining only and constituted essential parts of 
modules 1–4. Although frequent co-occurrence in texts does not seem to be the most confident evidence of asso-
ciation, we could not exclude it from consideration without losing 206 (62%) of shared genes.
We also found that all members of module 6 and almost all of module 5 included genes that are controlled 
by GWAS-identified eQTLs associated with asthma or hypertension. In total, 107 out of 330 shared genes were 
regulated by such eQTLs. Since this number significantly exceeded the expected by chance (Fisher’s exact test 
p-value < 6.94e-145; permutation p-value < 10e-4; 10 expected on average), we can hypothesize that these shared 
genes may have an impact on the development of comorbidity between asthma and hypertension. Importantly, 
this observation cannot be explained simply by shared GWAS hits. Only one missense variant, rs3184504 in 
SH2B3 gene, was in the intersection of asthma and hypertension GWAS associations. It was independently asso-
ciated with hypertension, blood eosinophil count and many other traits and controlled only 39 of 107 genes 
associated with asthma and hypertension through eQTL regulation. Interestingly, among these 39 genes 5 were 
up-regulated in blood of patients with hypertension and included in the “blood pressure signature” proposed by 
Huan et al.71: FOS, MYADM, PPP1R15A, S100A10, and TAGAP.
To illustrate the novelty of our findings, we compared our set of shared genes with gene sets obtained from 
Open Targets v18.02 and DisGeNET v5.0 using trivial disease names. In our list of 330 shared genes, 82 were 
novel (nodes shown in bold frames in Fig. 2), i.e. not associated with asthma and hypertension in OpenTargets 
and DisGeNET. These two large gene-disease association databases use distinct sets of evidence sources and 
interpret some associations differently. For example, they do not consider gene regulation data for establishing 
gene-disease associations, although it is implicated in asthma72 and hypertension71. Open Targets and DisGeNET 
include gene-disease associations obtained directly from GWAS Catalog, where disease-associated variants are 
mapped to neighboring genes and do not differentiate synonymous and non-synonymous variants. As a result, 
most of the newly identified shared genes were associated via eQTLs and composed modules 5 and 6.
Adverse drug reactions may mediate comorbidity of asthma and hypertension. We observed 
more common drugs (and therefore drug targets) relevant to asthma and hypertension than expected by chance. 
We composed four lists of drugs that influence asthma or hypertension (Supplementary Table S3): drugs with 
positive effects on asthma or hypertension (i.e. used to treat or relieve their symptoms) and drugs with negative 
effects on these diseases (i.e. contraindicated or worsening disease symptoms). Eight drugs used to treat hyper-
tension were harmful for asthma patients: timolol, nadolol, sotalol, pindolol, carvedilol, labetalol, propranolol. 
All these drugs belong to the class of non-selective beta-blockers and may exacerbate asthma19. At the same time, 
seven anti-asthmatic drugs occurred in the list of drugs that may increase the risk of hypertension or elevate 
blood pressure: triamcinolone, prednisolone, methylprednisolone, dexamethasone, hydrocortisone (corticos-
teroids) and epinephrine, ephedra, ephedrine (beta-agonists). Both overlaps were statistically significant with 
p-value < 2.64e-06 and p-value < 4.50e-06, respectively in Fisher’s exact test.
To find target genes whose activation or inhibition exhibit positive or negative influence on asthma and 
hypertension, we performed target overrepresentation analysis in four drug groups. 96 genes were significantly 
overrepresented among targets of at least one of four drug groups (Table 2 and Supplementary Table S4), only 
16 of which were in asthma-hypertension network. Interestingly, 8 of these 16 genes associated with asthma or 
hypertension through drug evidence appeared in module 4, enriched with genes involved in smooth muscle 
contraction. Figure 3 summarizes all significant drug targets, their relationships with drugs, and drug effects on 
asthma and hypertension. Supplementary Table S5 provides this network in tabular format. ADRB1 and ADRB2 
were targeted by drugs from all the four groups, and activation and inhibition of beta-adrenoreceptors caused 
opposite effects on asthma and hypertension. Similarly, NR3C1, a glucocorticoid receptor, was activated by drugs 
indicated in asthma but potentially harmful for hypertension. ANXA1 is another target of corticosteroid drugs, 
such as dexamethasone and hydrocortisone, its activation mediates the anti-inflammatory effect via inhibition of 
phospholipase A273. ANXA1 is up-regulated in blood of hypertensive patients71. PTGS2 inhibition seemed to have 
a negative effect on both diseases, while PTGS1 was overrepresented only among targets of drugs contraindicated 
in asthma.
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Our results agree with prior knowledge about asthma and hypertension medications. It is well known that β
-blockers and agonists have opposite effects on asthma and hypertension. Although medications for treating 
hypertension and asthma target different receptors (ADRB1 blockers have anti-hypertensive effect2 and ADRB2 
agonists have anti-asthmatic effect1), there are many components non-specifically targeting multiple types of 
adrenoreceptors19. Blockers of α1 and agonists of α2-adrenergic receptors cure hypertension2, and opposite 
actions on these receptors may provoke blood pressure elevation. Alternative treatment options for asthma 
patients who poorly respond to beta-agonists are inhaled or systemic glucocorticoids74. Overdosage of glucocor-
ticoids induces elevation of blood pressure, although inhaled glucocorticoids are relatively safe compared to sys-
temic steroids because of their local action21. Patients with an elevated level of glucocorticoids due to their 
overproduction or abnormal metabolism develop Cushing syndrome75, characterized by high blood pressure 
among other symptoms. Other classes of anti-inflammatory drugs, such as non-steroid anti-inflammatory drugs 
(NSAID) may also influence asthma and hypertension. NSAID-Exacerbated Respiratory Disease (NERD), is a 
classic example of adverse drug reaction in response to aspirin and some other NSAIDs. NERD is also called 
aspirin-induced asthma because it resembles main asthma symptoms, such as bronchial obstruction and dyspnea, 
and is prevalent among asthma patients76. NERD is thought to result from PTGS1 inhibition, therefore the usage 
of PTGS2 selective inhibitors is considered to be relatively safe for asthmatics77, but it is associated with a risk of 
hypertension78,79. Also, NSAIDs may decrease the effect of anti-hypertensive medications80.
Discussion
In this study, we investigated the genetic overlap between a pair of comorbid disorders, asthma and hypertension. 
A correlation of gene perturbation with disease status points to the possible involvement of this gene in the dis-
ease mechanism. At the same time, different molecular lesions may have similar effects on the phenotype. These 
considerations motivated us to construct two sets of genes independently associated with each disease through 
various perturbation types and investigate their overlap. We found 330 genes simultaneously associated with both 
diseases and potentially responsible for their comorbidity. Projecting these shared genes to an interaction net-
work revealed six functional modules comprising tightly interconnected genes. We tested these modules for the 
overrepresentation of GO terms and pathways, tissue-specificity and evidence types supporting gene associations.
We observed an excess of genes jointly controlled by asthma- and hypertension-associated eQTLs in mod-
ules enriched with genes involved in interferon-gamma signaling and chromatin assembly. This observation 
suggests that the coincidence of asthma and hypertension may be at least partially explained by concordantly 
altered genetic regulation of certain biological processes of functions. Our finding agrees with very recent results 
Figure 2. Evidence sources supporting gene associations with asthma and hypertension. In this figure, we used 
node style similar to Fig. 1B in103. Here, nodes represent genes associated with both asthma and hypertension, 
edges correspond gene interactions (only 257 nodes connected with at least one other node are shown). Genes 
are colored according to evidence sources (see figure legend) from which associations came from. The size 
of each node is proportional to the number of evidence sources supporting its association with asthma and 
hypertension. All 330 genes associated with asthma and hypertension annotated with evidence types supporting 
associations are listed in Supplementary Table S1.
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published by Li et al.81, who analyzed multiple disease pairs and demonstrated that comorbid diseases share sig-
nificantly more eQTL-regulated transcripts than expected by chance.
We also found more drugs with opposite effects on asthma and hypertension than expected by chance. Based 
on this observation, we hypothesized that comorbidity might be the result of drug side effects, when drugs against 
one disease may predispose the patient to the development of another. This particular case of asthma and hyper-
tension demonstrates that genes targeted by contraindicated drugs may also participate in pathophysiologic 
mechanisms of comorbidity.
An important limitation of this study is the absence of direct validation of the resulting associated gene set. 
Since the genetic basis of asthma and hypertension comorbidity is poorly understood, we have no gold stand-
ard to compare with. Another way of result evaluation would be an experimental validation of gene roles in the 
comorbidity, which was not in the scope of this work.
The validity of our results is partially confirmed by the presence of some known shared genes in our set. Four 
genes (ADRB1, ADRB2, TLR4, and CD14) listed in Table 1 appear among 330 genes associated with asthma and 
hypertension. This limited overlap may be explained by the fact that most of the papers included in Table 1 do not 
focus on asthma or hypertension and only list them among multiple phenotypes associated with certain genes. 
Therefore, if associations of these genes with asthma and hypertension do not appear in abstracts, they remain 
invisible for text mining tools.
Another indirect confirmation of the result validity is our observation that comorbid diseases share many 
genes controlled by eQTLs. This agrees with the results of Li et al.81, obtained independently on different datasets.
Methods
Monogenic associations via hereditary asthma and hypertension. From MalaCards82 v4.5, and 
literature2,83 we extracted genes that carry mutations causing monogenic syndromes with asthma or hyperten-
sion among other symptoms. In total, we found 37 genes associated with familial forms of hypertension or with 
Mendelian disorders characterized by hypertension. No monogenic forms of asthma were found, although several 
Mendelian syndromes characterized by frequent asthma attacks considered in the literature83. From human phe-
notype ontology84 (HPO) we selected phenotype terms related to asthma (HP:0002099 - Asthma, HP:0012042 
- Aspirin-induced asthma, HP:0025428 - Bronchospasm) and hypertension (HP:0000822 - Hypertension, 
HP:0000875 - Episodic hypertension, HP:0004421 - Elevated systolic blood pressure, HP:0004972 - Elevated 
mean arterial pressure, HP:0005117 - Elevated diastolic blood pressure). We excluded genes associated with spe-
cific kinds of hypertension (e.g. ocular hypertension) that are not related to essential hypertension (HP:0007906, 
HP:0001409, HP:0002092, HP:0002640, HP:0008071, HP:0100817, HP:0005168). Mapping of genes to HPO 
terms was downloaded from http://compbio.charite.de/jenkins/job/hpo.annotations.monthly/lastStableBuild/, 
table ALL_SOURCES_FREQUENT_diseases_to_genes_to_phenotypes.txt” available on 26.01.2018. We used 
gene-phenotype pairs marked as “frequent”, which means that this phenotype was manifested in at least 50% 
patients with a disease.
coding GWAS variants. GWAS Catalog85 v1.0.1 (downloaded on 22.08.2017) includes 29 studies related 
to asthma which report 407 associations in total (395 unique). In addition, we included 17 associations from 4 
studies of asthma-related traits such as NERD, eosinophil count or Immunoglobulin E (IgE) levels. Similarly, 
120 associations with hypertension and blood pressure traits were obtained from 16 studies listed in GWAS 
Catalog. All associations have p-value < 10e-5 (default in GWAS Catalog). Only 29 and 9 single-nucleotide pol-
ymorphisms (SNPs) associated with asthma and asthma-related traits and with hypertension and blood pressure 
respectively were annotated as splice_region_variant, missense_variant, synonymous_variant or non_coding_
transcript_exon_variant and therefore affected transcript sequences.
Regulation. Although only a small fraction of variants discovered in GWAS affects transcripts, about a half 
of them overlap with eQTLs86. From three recent blood eQTL studies86–88 comprising thousands of individuals, 
we obtained lists of eQTL SNPs and overlapped them with variants associated with asthma and hypertension 
Disease Drug Group # Drugs # Targets Drug Targets Overrepresented in the Group
asthma indications 61 81 ADORA1, ADORA2A, ADORA2B, ADORA3, ADRB1, ADRB2, ADRB3, ANXA1, CYSLTR1, HDAC2, IL5, NR3C1, PDE3A, PDE4A, PDE4B, PDE4C
asthma contraindications 45 142 ABCC1, ABCC2, ADRB1, ADRB2, AKR1C3, ALOX5, IKBKB, KCNQ2, KCNQ3, PPARA, PPARG, PRKAA1, PRKAB1, PRKAB2, PTGDR2, PTGS1, PTGS2
hypertension indications 99 128
ACE, ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRB1, ADRB2, 
AGTR1, AGTR2, BDKRB1, CA1, CA4, CACNA1B, CACNA1C, CACNA1D, 
CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, 
CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, KCNH2, KCNH6, KCNH7, 
NR3C2, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC12A1, SLC12A3
hypertension contraindications 94 188
ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, 
ADRB2, ADRB3, ANXA1, FGA, FLT1, FLT4, HTR1A, HTR1B, HTR1D, 
HTR1E, HTR1F, HTR2B, HTR2C, HTR7, ITGA2B, ITGB3, MAOA, MAOB, 
NR3C1, PAH, PDGFRB, PGR, PLAUR, PLG, PTGS2, SERPINB2, SERPINE1, 
SLC18A1, SLC18A2, SLC6A2, SLC6A3, SLC6A4, TAAR1, VKORC1
Table 2. Genes overrepresented among targets of drugs influencing asthma and hypertension. Target genes 
significantly enriched in more than one group are shown in bold. Genes ADRB1 and ADRB2 whose potential 
role in asthma and hypertension was previously discussed are underlined.
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in GWAS. Furthermore, we included variants associated with tissue-specific expression from GTEx v689. This 
dataset contained eQTLs in 44 tissues including whole blood. The details of eQTL data sources used in this study 
are presented in Table 3. From each study, we retained only SNP-gene pairs which passed the false discovery rate 
(FDR) threshold of 0.05. All SNPs coordinates were lifted over to hg38 and their IDs were converted into dbSNP90 
v150 to match SNPs IDs used in GWAS catalog.
Differentially expressed genes. We obtained asthma and hypertension expression signatures from the 
two biggest expression profiling studies of blood pressure71 and asthma91. From Huan et al. we took 34 genes with 
expressions associated with hypertension diagnosis or with systolic and diastolic blood pressure. Asthma expres-
sion signature included 541 genes differentially expressed in the blood of asthma patients in Bigler et al. dataset. 
In addition to these two signatures, we composed two lists of genes that demonstrated altered expression levels 
in asthma or hypertension according to ANDSystem (published on 09.10.2014) and DisGeNET v5.0. These two 
resources provide collections of differentially expressed genes automatically extracted from biomedical literature. 
To reduce false positives, we took genes whose altered expression in asthma and hypertension was supported by 
at least two evidence sources.
Drugs and drug targets. Drugs indicated and contraindicated in asthma and hypertension were obtained 
from DrugBank92 v5.0.9 and NDF-RT93 (released on 02.10.2017). Surprisingly, 5 anti-asthmatic drugs (budeso-
nide, flunisolide, salmeterol, formoterol, and cromoglicic acid) were at the same time contraindicated in asthma 
according to NDF-RT. These drugs are known to cause paradoxical drug reactions, for example, when the intake 
of an anti-asthmatic drug provokes bronchospasm94. We excluded such drugs from contraindications list but kept 
them in the list of indications, because paradoxical reactions are extremely rare. Finally, the list of contraindicated 
drugs was extended with drugs reported to induce the rise of blood pressure and asthma, NERD or bronchos-
pasms. From DrugBank, we obtained genes targeted by selected drugs. All target genes encoding non-human 
proteins were excluded. All drug action types used in DrugBank were converted to simplified effects reflecting 
the direction of drug action on its target, e.g. “positive” for agonists and activators, “negative” for inhibitors and 
antagonists, and “other” for modifiers. Supplementary Table S3 contains selected drugs, their effects on diseases 
and their targets.
Statistical tests. Gene set overrepresentation tests were carried out in TargetMine95 (build 20180327) with 
default parameters (one-tailed Fisher’s exact test followed by Benjamini-Hochberg correction for multiple testing; 
Figure 3. Relationships between genes and drugs indicated and contraindicated in asthma and hypertension. 
All target genes significantly overrepresented in one of four drug groups are shown. Drugs influencing both 
diseases and target genes overrepresented in more than one group are shown with bold frames.
Dataset samples Tissue or cell type Cis-eQTLs Trans-eQTLs
GTEx v6 449 44 tissues including whole blood 639825 24
Westra et al.87 5311 PBMC 397310 349
Joehanes et al.86 5257 whole blood 2072003 149592
Jansen et al.88 4896 whole blood 1212555 6913
Table 3. Characteristics of eQTL datasets.
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p-value threshold 0.05; all genes from the tested database were considered as the background set). Similarly, over-
representation of drug targets in groups of drugs evaluated using the one-sided Fisher’s exact test implemented 
in scipy python library. We considered all the drugs from DrugBank with defined action on any human target as 
the background, and applied p-value threshold of 0.05 after Benjamini-Hochberg correction for multiple testing.
To demonstrate that asthma and hypertension share more eQTL regulated genes than expected by chance, 
we generated 10000 pairs of random eQTL sets and calculated the number of shared genes for each pair. Sizes 
and overlap of randomly generated eQTL sets were set the same as real sets of asthma and hypertension eQTLs.
Data availability
All data generated during this study are included in Supplementary Information files.
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